Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Advances in Natural Killer Cell Therapies for Breast Cancer Publisher Pubmed



Kiaei SZF1 ; Nouralishahi A2 ; Ghasemirad M3 ; Barkhordar M4 ; Ghaffari S5 ; Kheradjoo H6 ; Saleh M7 ; Mohammadzadehsaliani S8 ; Molaeipour Z9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pulmonary and Critical Care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Periodontics, Faculty of Dentistry, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  4. 4. Hematology, Oncology and Stem Cell Transplantation Research Center (HORCSCT), Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
  6. 6. Laboratory Department, Buraimi Hospital, Buraimi, Oman
  7. 7. Wisconsin National Primate Research Center, University of Wisconsin Graduate School, Madison, WI, United States
  8. 8. Ophthalmology Department, Buraimi Hospital, Buraimi, Oman
  9. 9. Hematology Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Immunology and Cell Biology Published:2023


Abstract

Breast cancer (BC) is the most common cause of cancer death in women. According to the American Cancer Society's yearly cancer statistics, BC constituted almost 15% of all the newly diagnosed cancer cases in 2022 for both sexes. Metastatic disease occurs in 30% of patients with BC. The currently available treatments fail to cure metastatic BC, and the average survival time for patients with metastatic BC is approximately 2 years. Developing a treatment method that terminates cancer stem cells without harming healthy cells is the primary objective of novel therapeutics. Adoptive cell therapy is a branch of cancer immunotherapy that utilizes the immune cells to attack cancer cells. Natural killer (NK) cells are an essential component of innate immunity and are critical in destroying tumor cells without prior stimulation with antigens. With the advent of chimeric antigen receptors (CARs), the autologous or allogeneic use of NK/CAR–NK cell therapy has raised new hopes for treating patients with cancer. Here, we describe recent developments in NK and CAR–NK cell immunotherapy, including the biology and function of NK cells, clinical trials, different sources of NK cells and their future perspectives on BC. © 2023 the Australian and New Zealand Society for Immunology, Inc.
Related Docs
View other Related Docs
1. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
2. The Nexus of Natural Killer Cells and Melanoma Tumor Microenvironment: Crosstalk, Chemotherapeutic Potential, and Innovative Nk Cell-Based Therapeutic Strategies, Cancer Cell International (2023)
3. Engaging Stemness Improves Cancer Immunotherapy, Cancer Letters (2023)
4. Optimization of in Vitro Expansion and Activation of Human Natural Killer Cells Against Breast Cancer Cell Line, Avicenna Journal of Medical Biotechnology (2020)
5. Advances in Bioengineered Car T/Nk Cell Therapy for Glioblastoma: Overcoming Immunosuppression and Nanotechnology-Based Strategies for Enhanced Car T/Nk Cell Therapy, Bioengineering and Translational Medicine (2024)
6. A Novel Car Expressing Nk Cell Targeting Cd25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers, Frontiers in Oncology (2021)
7. Cancer Exosomes and Natural Killer Cells Dysfunction: Biological Roles, Clinical Significance and Implications for Immunotherapy, Molecular Cancer (2022)
8. More Balance Toward Activating Receptors and Cytotoxic Activity of Nk Cells Ex Vivo Differentiated From Human Umbilical Cord Blood-Derived Cd34+ Stem Cells in Comparison With Peripheral Blood Nk Cells, Heliyon (2024)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (6)
Nafiseh Esmaeil (4)
Other Related Docs
9. Flip-Flops of Natural Killer Cells in Autoimmune Diseases Versus Cancers: Immunologic Axis, Journal of Cellular Physiology (2019)
10. Investigation of Kir/Hla Relationship and Other Clinical Variables After T-Cell-Replete Haploidentical Bone Marrow Transplantation in Patients With Acute Myeloid Leukemia (Aml), BMC Immunology (2023)
11. Strong Capacity of Differentiated Pd-L1 Car-Modified Ucb-Cd34+ Cells and Pd-L1 Car-Modified Ucb-Cd34+-Derived Nk Cells in Killing Target Cells and Restoration of the Anti-Tumor Function of Pd-1-High Exhausted T Cells, Stem Cell Research and Therapy (2024)
12. The Influence of Kir Gene Polymorphisms and Kir-Ligand Binding on Outcomes in Hematologic Malignancies Following Haploidentical Stem Cell Transplantation: A Comprehensive Review, Current Cancer Drug Targets (2023)
13. The Molecular Perspective on the Melanoma and Genome Engineering of T-Cells in Targeting Therapy, Environmental Research (2023)
14. Effect of Plasma-Derived Exosomes of Refractory/Relapsed or Responsive Patients With Diffuse Large B-Cell Lymphoma on Natural Killer Cells Functions, Cell Journal (2020)
15. Spirulina Extract Enriched for Braun-Type Lipoprotein (Immulina®) for Inhibition of 4T1 Breast Tumors' Growth and Metastasis, Phytotherapy Research (2020)
16. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
17. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)
18. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)
19. Cancer Vaccines As a Targeted Immunotherapy Approach for Breast Cancer: An Update of Clinical Evidence, Expert Review of Vaccines (2022)
20. Oncolytic Virotherapy Improves Immunotherapies Targeting Cancer Stemness in Glioblastoma, Biochimica et Biophysica Acta - General Subjects (2024)
21. Association of Killer Cell Immunoglobulin-Like Receptors and Their Cognate Hla Class I Ligands With Susceptibility to Acute Myeloid Leukemia in Iranian Patients, Scientific Reports (2023)
22. Computational Study for Suppression of Cd25/Il-2 Interaction, Biological Chemistry (2021)
23. Genetically Engineered Mesenchymal Stem Cells: Targeted Delivery of Immunomodulatory Agents for Tumor Eradication, Cancer Gene Therapy (2020)
24. Mesenchymal Stem Cells: A New Platform for Targeting Suicide Genes in Cancer, Journal of Cellular Physiology (2018)
25. Induced Pluripotent Stem Cell As a New Source for Cancer Immunotherapy, Genetics Research International (2016)
26. Advances in Targeted Nano-Delivery of Bevacizumab Using Nanoparticles: Current Insights, Innovations, and Future Perspectives, Journal of Drug Delivery Science and Technology (2024)
27. Chimeric Antigen Receptor-T Cells Immunotherapy for Targeting Breast Cancer, Research in Pharmaceutical Sciences (2021)
28. Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy, Stem Cell Research and Therapy (2022)
29. Pathogenic and Therapeutic Roles of Cytokines in Acute Myeloid Leukemia, Cytokine (2021)
30. The Role of Nk and Nkt Cells in the Pathogenesis and Improvement of Multiple Sclerosis Following Disease-Modifying Therapies, Health Science Reports (2022)
31. Regulating the Regulatory T Cells As Cell Therapies in Autoimmunity and Cancer, Frontiers in Medicine (2023)
32. The Decrease in Nkg2d+ Natural Killer Cells in Peripheral Blood of Patients With Metastatic Colorectal Cancer, Bratislava Medical Journal (2015)
33. Expression of Basal and Luminal Cytokeratins in Breast Cancer and Their Correlation With Clinicopathological Prognostic Variables, Indian Journal of Medical Sciences (2009)
34. Regenerative Medicine in Covid-19 Treatment: Real Opportunities and Range of Promises, Stem Cell Reviews and Reports (2021)
35. Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents, Current Medicinal Chemistry (2016)
36. Using Classification and K-Means Methods to Predict Breast Cancer Recurrence in Gene Expression Data, Journal of Medical Signals and Sensors (2022)
37. Mesenchymal Stem Cell-Released Oncolytic Virus: An Innovative Strategy for Cancer Treatment, Cell Communication and Signaling (2023)
38. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)
39. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)